论文部分内容阅读
目的建立显微镜血尿方法与尿红细胞(RBC)计数的诊断界线,证实可以列入筛查泌尿道肿瘤的程序。方法调查3批军人和一批地方体检尿分析尿红细胞,研究总结泌尿系统肿瘤574例住院病人尿红细胞(RBC)计数。结果尿试条潜血特异性为94.6%。尿沉渣定量板诊断界线为RBC≤8/μl,此相当于尿沉渣镜检RBC 0~3/hp。在10例显微镜血尿>50岁者中查出1例膀胱癌。临床106例膀胱癌病人尿红细胞为237±524/μl;门诊231例体检者尿红细胞为0.3±2.0/μl。结论尿红细胞计数RBC≥9/μl,可作为膀胱上皮细胞癌初筛标志物,显微镜血尿继以尿道造影术、尿道膀胱镜、细胞学证实。
Objective To establish a diagnostic boundary between microscopic hematuria and urinary red blood cell (RBC) count and confirm that it can be included in the screening procedure for urological tumors. Methods Three batches of soldiers and a group of local urine tests were used to investigate urine red blood cells (RBCs). 574 inpatients with urinary tract tumors were enrolled in this study. Results Urine test strip occult blood specificity was 94.6%. Urine sediment quantitative diagnostic limit line RBC ≤ 8 / μl, which is equivalent to urinary sediment microscopy RBC 0 ~ 3 / hp. One case of bladder cancer was found in 10 cases of microscopic hematuria> 50 years old. Clinical 106 patients with bladder cancer urinary red blood cells for 237 ± 524 / μl; outpatient 231 cases of urine urine of patients with 0.3 ± 2.0 / μl. Conclusions RBC count of RBC≥9 / μl can be used as a primary screening marker of bladder epithelial cell carcinoma. Microscopic hematuria followed by urethroplasty, urethral cystoscopy and cytology were confirmed.